Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model
about
What is the role of respiratory viruses in community-acquired pneumonia?: What is the best therapy for influenza and other viral causes of community-acquired pneumonia?Cytomegalovirus antivirals and development of improved animal modelsSolution Structure of a DNA Duplex Containing the Potent Anti-Poxvirus Agent CidofovirAdvances in antivirals for non-influenza respiratory virus infections.HAdV-C6 Is a More Relevant Challenge Virus than HAdV-C5 for Testing Antiviral Drugs with the Immunosuppressed Syrian Hamster Model.Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirusPre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster modelAcanthamoeba castellanii is not be an adequate model to study human adenovirus interactions with macrophagic cells.Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging.Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium.Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters.An immunosuppressed Syrian golden hamster model for SARS-CoV infection.Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.Inhibition of adenovirus replication by a trisubstituted piperazin-2-one derivative.Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamstersIncreasing the efficacy of oncolytic adenovirus vectorsBacks against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreakSTAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral ControlUpdate on new antivirals under development for the treatment of double-stranded DNA virus infectionsTranscriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters.An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.A fully replication-competent adenovirus vector with enhanced oncolytic propertiesManagement of respiratory viral infections in hematopoietic cell transplant recipients.New drug on the horizon for treating adenovirusEffect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical StudiesA lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus.Oncolytic (replication-competent) adenoviruses as anticancer agents.The search for new therapies for human cytomegalovirus infections.Adenoviral load diagnostics by quantitative polymerase chain reaction: techniques and application.Highlights in antiviral drug research: antivirals at the horizon.Diagnosis and treatment of adenovirus infection in immunocompromised patients.Development of Small-Molecule Antivirals for Ebola.Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.
P2860
Q26852219-E655B2EE-1AD8-41D1-9AF0-A8771AD56098Q27000998-8F99927A-143E-4245-A2AA-32E6E2B286CBQ27666791-15D0B499-DCDB-4DEB-B40B-D2283110B387Q30457132-EAC9294E-70EC-4956-B843-217D46846D05Q32183133-F7C995E6-6EE5-4B06-BA21-44F329C14C40Q33622711-F1EB3128-FFC6-4742-BB5E-37B4015859BAQ33690982-D15A8072-304A-42E8-A7AD-207B86EF65BAQ33713048-CA2526B0-514F-48AF-9D7F-9881B0E954B5Q33773030-FAFC344C-9C19-41DB-BF62-712192AEBE64Q33803963-09782EC0-38DB-4477-81B8-683461B2C901Q33937843-6367B1D7-F1A6-4151-B255-68F85CDB1CFCQ34483696-D86BE3E9-72D2-43CA-B50F-078DB64CDE08Q34597872-310EB204-DA41-4716-BD2B-4EDCE0503AE7Q34818143-2D53ABD1-0457-4309-838C-8FEFE2B857CFQ35013420-96796A12-476E-4A79-8B9E-D990FF0FFA59Q35183338-0CAFCB82-548A-403C-A110-8AD54E40DC13Q35232836-3B591AC4-BE53-4CCB-A870-9DD3A2BD980FQ35261325-79C8B08B-5C8A-4AA4-989E-45A0E3CB04F6Q35598919-EEA79C29-C640-4D64-AF96-860398D344D9Q35751170-D94BA50A-4E11-463A-B861-51AF4D495827Q36185647-EE006F1E-2D91-4BF9-B6C6-465C72DBC6F6Q36202563-DEEAD472-7F67-49DE-BE5A-025BBD53DFE7Q36209165-BCC2879D-F4B5-4BD8-A58F-D7889E8E29DFQ36209172-DC1EE526-9B8F-482C-9C54-9425FEB7D7E3Q36209205-CD026186-40E9-4B63-957D-951770FEE498Q36221367-FE61540B-680D-48C7-9230-A58AB4B1BEC6Q36439896-FEBDD5D8-2853-4582-99B6-E221CAC9C4AFQ36900283-962778F4-0A39-46B6-B859-95F6611A0248Q37099738-8868E457-1BD4-4DEE-9C87-EC747AC137EBQ37401749-D5BF98C2-3C87-4BC1-9964-6574FE5C9415Q37420102-446E24A6-A71F-487B-820A-776EA345F277Q37547578-80DE2495-C3F3-475A-BE8E-4C9DCC410F1BQ37687415-9B751104-A24C-4AD3-A5FD-D929D69A5E73Q37811458-10FEC694-105F-4308-BC81-153BC2A68DCBQ37967604-1CB52A03-8648-4A23-8CF0-46D6C2B480EAQ38007145-41AE4EE8-2CC8-4BFE-8DE7-D5FF39C4AC5AQ38145327-DAE025F8-7EC6-4B26-82AE-23B31FC27819Q38546746-1AD35589-B047-47FF-8C2A-D45524A329E5Q38714311-6D55B96E-5853-4D3D-801E-33089C199F4AQ38811582-1CC1B284-1EC3-4D73-A7CE-88473AC18B29
P2860
Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Hexadecyloxypropyl-cidofovir, ...... immunosuppressed animal model
@ast
Hexadecyloxypropyl-cidofovir, ...... immunosuppressed animal model
@en
type
label
Hexadecyloxypropyl-cidofovir, ...... immunosuppressed animal model
@ast
Hexadecyloxypropyl-cidofovir, ...... immunosuppressed animal model
@en
prefLabel
Hexadecyloxypropyl-cidofovir, ...... immunosuppressed animal model
@ast
Hexadecyloxypropyl-cidofovir, ...... immunosuppressed animal model
@en
P2093
P2860
P356
P1476
Hexadecyloxypropyl-cidofovir, ...... immunosuppressed animal model
@en
P2093
Debanjan Dhar
George R Painter
Jacqueline F Spencer
John E Sagartz
Karoly Toth
R Mark L Buller
William S M Wold
P2860
P304
P356
10.1073/PNAS.0800200105
P407
P577
2008-05-19T00:00:00Z